STING agonists can synergize with anti-PD-L1 therapy to enhance the levels of IFN-β, IFN-γ, TNF-α and IL-10 as well as CD8 cytotoxic function in the breast cancer mouse model (Yin et al., 2022). Here, STING1 is linked to breast cancer.